Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance (RSV)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Albert Einstein College of Medicine, Inc..
Recruitment status was:  Recruiting
American Diabetes Association
Information provided by:
Albert Einstein College of Medicine, Inc. Identifier:
First received: May 12, 2011
Last updated: June 16, 2011
Last verified: June 2011
Resveratrol is a substance found in many plants, including grapes and red wine, which is widely used as a nutritional supplement. Studies in cells and lower animals show that resveratrol has many potential benefits, including prolonging lifespan, preventing cancer and heart disease and normalization of glucose metabolism. Although use of this agent shows great promise in the treatment and/or prevention of diabetes, there have been no studies reported to date in humans. As an initial step, this proposal is for a 6 week pilot study of resveratrol treatment in older adults with impaired glucose tolerance (IGT) in order to explore its effects on post-meal blood glucose metabolism. Preliminary studies will also be conducted to explore how resveratrol works by studying cellular function (in muscle samples obtained from study participants) and by testing resveratrol's effect on blood vessel function.

Condition Intervention
Impaired Glucose Tolerance
Dietary Supplement: resveratrol
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Resveratrol in Older Adults With Impaired Glucose Tolerance: a Double-Blind Crossover Study

Resource links provided by NLM:

Further study details as provided by Albert Einstein College of Medicine, Inc.:

Primary Outcome Measures:
  • post meal glucose area under the curve [ Time Frame: end of each of two 6 week treatment periods ]
    Glucose AUC following a standard mixed meal challenge

Secondary Outcome Measures:
  • insulin sensitivity [ Time Frame: end of each of two 6 week treatment periods ]

Estimated Enrollment: 30
Study Start Date: April 2011
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: resveratrol Dietary Supplement: resveratrol
resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
Other Names:
  • RevGenetics
  • X500 Resveratrol
Placebo Comparator: placebo Drug: Placebo
3 placebo capsules orally twice a day for 6 weeks


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • impaired glucose tolerance

Exclusion Criteria:

  • history of estrogen-dependent neoplasm
  • use of certain drugs: high dose statins, warfarin, antiepileptics
  • current treatment with anti-diabetes medications
  • impaired liver or kidney function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01375959

Contact: Migdalia Reid, RN, MPH 718-405-8271

United States, New York
Albert Einstein College of Medicine of Yeshiva University Recruiting
Bronx, New York, United States, 10461
Sponsors and Collaborators
Albert Einstein College of Medicine, Inc.
American Diabetes Association
Principal Investigator: Jill Crandall, MD Albert Einstein College of Medicine, Inc.
  More Information

Responsible Party: Jill Crandall MD, Albert Einstein College of Medicine of Yeshiva University Identifier: NCT01375959     History of Changes
Other Study ID Numbers: 2010-398
Study First Received: May 12, 2011
Last Updated: June 16, 2011

Keywords provided by Albert Einstein College of Medicine, Inc.:
glucose intolerance
insulin resistance
endothelial function

Additional relevant MeSH terms:
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents processed this record on May 24, 2017